The Ledger

Up to 145 million dollars: that is what Teva Pharmaceuticals is paying for a bankrupt Connecticut drugmaker’s entire neuroscience portfolio, in a deal struck the same week the company ran out of cash. BioXcel Therapeutics, a New Haven biopharmaceutical company, filed for Chapter 11 bankruptcy protection August 27, 2026 in the U.S. Bankruptcy Court for the District of Delaware and simultaneously entered a stalking horse asset purchase agreement with Teva Pharmaceuticals, a major generic and specialty drugmaker, to buy substantially all of BioXcel’s assets. Under the agreement, Teva would pay 57.5 million dollars in upfront cash and assume certain liabilities, plus up to 67.5 million dollars more in contingent milestone payments tied to the timing and outcome of a pending Food and Drug Administration (FDA) decision, expected November 14, 2026, on expanded at-home use of Igalmi (dexmedetomidine), BioXcel’s only approved product, a sublingual film for agitation associated with schizophrenia or bipolar I or II disorder. BioXcel said in court filings that the bankruptcy stemmed from a slower than anticipated commercial launch of Igalmi, citing extended hospital formulary review timelines, restrictive institutional purchasing protocols, and the need for sustained physician education to change established prescribing habits; the company also secured 19 million dollars in debtor in possession financing to fund operations through the sale process, and BioXcel chief executive Vimal Mehta said the agreement “provides a clear framework to pursue a value-maximizing transaction.” Confidence: High on the bankruptcy filing and deal structure, drawn from BioXcel’s own investor announcement and corroborating bankruptcy-docket reporting. Medium on the total deal value, which trade outlets have reported variably as up to 125 million or up to 145 million dollars depending on how liabilities assumed are counted. Sources: BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals, BioXcel Therapeutics Investor Relations, BioXcel Therapeutics Files for Ch. 11 Bankruptcy in Delaware, Bloomberg Law, Teva saddles up as stalking horse bidder for bankrupt BioXcel’s neuroscience portfolio, Fierce Biotech.

162,000 dollars: that is the annual revenue one rural Hawaii doctor’s office expects to lose starting tomorrow, when the state’s dominant insurer reverses a value-based payment model back to old-style fee-for-service. HMSA (Hawaii Medical Service Association), a Blue Cross Blue Shield licensee that covers most of Hawaii’s commercially and Medicare Advantage insured residents, is shifting independent primary care providers off fixed monthly “transformation” payments and back onto traditional fee-for-service billing, with an early-transition option beginning September 1, 2026 that carries a 15 percent payment incentive for neighbor-island providers, and a final deadline of January 1, 2027 for everyone else, after Hawaii Governor Josh Green intervened to push back an original July 1, 2026 cutoff. HMSA is pairing the shift with new claims-based patient-attribution rules that drop patients who have been inactive for 18 months or more from a provider’s panel, and that pay only one provider, whichever saw the patient more often, when a patient visits multiple primary care doctors in a year. Dr. Kaleo Correa, founder of Waimea Primary Care on Hawaii Island, said the changes could strip roughly 450 patients, nearly 40 percent of his HMSA-covered roster, costing his practice about 162,000 dollars in annual revenue, and called the shift “a shake-up. I can’t operate a business not knowing how we’re going to get paid”; Hilo Family Medicine has already announced it will close September 30, 2026. HMSA president Jenny Smith said the insurer is “updating its Primary Care Payment Model to create a clearer, claims-based foundation.” The payment fight lands as HMSA separately pursues state regulatory approval to merge with Hawaii Pacific Health into a combined entity to be called One Health Hawaii, a deal that would deepen the insurer’s reach into the same provider market it is now repricing. Confidence: Medium. This run relied on direct local newspaper reporting that quoted HMSA’s president and affected physicians; HMSA has not published its own consumer-facing policy notice for independent review this run. Source: Private-practice doctors alarmed by HMSA policy changes, Hawaii Tribune-Herald.

800: that is how many radiologists across more than 40 countries a US physician-services giant is absorbing, in a global teleradiology deal trade press pegs near 1 billion dollars. Radiology Partners, the largest radiology physician practice in the United States and parent of the vRad teleradiology platform, announced August 25, 2026 a definitive agreement to acquire Everlight Radiology, a London and Sydney headquartered teleradiology network majority owned by private equity firm Livingbridge since 2021 that coordinates more than 800 consultant radiologists across over 40 countries, reads more than 2.5 million exams a year, and serves more than 340 client organizations across the United Kingdom, Ireland, Australia, New Zealand, and South Africa. Combined with vRad’s roughly 500 US board-certified radiologists serving more than 3,400 hospitals, Radiology Partners chief executive Rich Whitney said the deal lets the companies “bring the best of what each has built to a growing number of patients and hospitals,” while Everlight chief executive Rob Anderson said Everlight will keep “the same teams, the same standards” under the combination. Neither company disclosed a purchase price; the Australian Financial Review has reported it at approximately 715 million dollars citing people familiar with the matter, while other outlets have cited a figure near 1 billion dollars. Rothschild and Co. and Barclays advised on the transaction, which still requires customary regulatory clearances across the markets involved before it closes. Confidence: High on the deal structure and combined footprint, drawn from Radiology Partners’ own announcement. Low on valuation, which remains unconfirmed by either party. Sources: Radiology Partners to Acquire Everlight Radiology, Creating a Global Leader in Teleradiology, Radiology Partners, Radiology Partners to acquire Everlight Radiology in $1 billion deal, AuntMinnie.

37.3 million dollars: that is the new funding behind an AI platform already used by 6 of the world’s 10 largest pharmaceutical companies to plan and run clinical trials. Faro AI, a San Diego company that builds structured-data and agentic AI infrastructure for clinical development, announced August 26, 2026 it raised 37.3 million dollars in Series B financing co-led by Merck Global Health Innovation Fund, the venture arm of drugmaker Merck, and life-sciences investor S32, with participation from existing backers General Catalyst, Northpond Ventures, Polaris Partners, PTX Capital, and Zetta, plus new investor Ankona Capital. Founded in 2019 by chief executive Scott Chetham and Ross A. Jaffe, Faro says its platform is now used by six of the world’s ten largest pharmaceutical companies to model clinical development programs across a broad range of therapeutic areas and study designs; the new round brings Faro’s total funding to roughly 76 million dollars, and the company plans to use the capital to expand its AI agents’ role in the processes that move a drug from first-in-human studies through FDA approval. Confidence: High on the funding terms and investor list, drawn from the company’s own announcement and corroborating trade coverage. Source: Faro Raises $37.3M Series B to Scale Agentic AI Across Clinical Development, citybiz.

5 billion dollars: that is the annual claims value now running through an AI platform built to catch the revenue hospitals are quietly leaving on the table, the reason it just raised its own Series B. Arintra, an AI platform that audits hospital and clinic billing for missed or miscoded revenue across inpatient, outpatient, ambulatory, and emergency care settings, announced August 27, 2026 it raised 25 million dollars in Series B funding led by Define Ventures, with participation from Peak XV Partners, Yale New Haven Health’s Center for Health Care Innovation, Endeavor Health Ventures, Y Combinator, Counterpart Ventures, Ten13, and Spider Capital. Founded in 2020, Arintra says its platform now drives 5 billion dollars in annual claim value for health systems, large provider groups, and academic medical centers by improving documentation, coding accuracy, and denial rates; the new round brings Arintra’s total funding to 51 million dollars, which the company plans to use to expand into more health systems and add capabilities across the revenue cycle. Confidence: High on the funding terms and investor list, drawn from the company’s own release and corroborating trade coverage. Sources: Arintra Raises $25M to Pioneer Revenue Assurance for America’s Health Systems, BioSpace, Arintra banks $25M Series B funding round for AI-driven revenue assurance platform, Fierce Healthcare.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
BioXcel Therapeutics (substantially all assets)	Teva Pharmaceuticals, as stalking horse bidder in Chapter 11 sale	Biopharma, neuroscience/agitation therapeutics	57.5 million dollars upfront plus up to 67.5 million dollars in milestones; filed August 27, 2026	BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals, BioXcel Therapeutics Investor Relations
Everlight Radiology	Radiology Partners	Teleradiology, physician services consolidation	715 million to 1 billion dollars (unconfirmed); announced August 25, 2026	Radiology Partners to Acquire Everlight Radiology, Radiology Partners
Faro AI	Merck Global Health Innovation Fund and S32 (co-led), General Catalyst, Northpond Ventures, Polaris Partners, PTX Capital, Zetta, Ankona Capital	Clinical-trials AI and data infrastructure	37.3 million dollar Series B; announced August 26, 2026	Faro Raises $37.3M Series B to Scale Agentic AI Across Clinical Development, citybiz
Arintra	Define Ventures (led), Peak XV Partners, Yale New Haven Health Center for Health Care Innovation, Endeavor Health Ventures, Y Combinator, Counterpart Ventures, Ten13, Spider Capital	Revenue cycle AI / healthcare billing	25 million dollar Series B; announced August 27, 2026	Arintra Raises $25M to Pioneer Revenue Assurance for America’s Health Systems, BioSpace

This run’s scan of PE Hub, FTC, and DOJ merger actions and state transaction-review dockets found no new healthcare antitrust complaints or consent orders in the last 24 to 48 hours. A frontier check on hospital landlord and sale-leaseback real estate investment trusts, a Ledger branch not touched in the last three issues, found no fresh deal or earnings news dated to this window; worth checking again once Medical Properties Trust’s next tenant restructuring update lands.